



Colorado BioScience ASSOCIATION



FOCUS

MARCH
2011

Letter from the President



This year, due to the increased legislation affecting our industry, CBSA has been working closely with members of our congressional delegation on federal policy issues along-side our national partners including AdvaMed, BIO, MDMA and

PhRMA. Congress is currently reviewing legislation regarding FDA, Healthcare, Patent reform, SBIR reauthorization and funding for NIH.

Over the past several months we have had a series of meetings and call-ins with Senator Bennett and Udall's offices to provide direct feedback with assistance from many of our dedicated members. In the coming weeks, we will have a new set of Federal Policy priorities we have been developing to share with you. We want to relay our message to congress that innovation and global competitiveness in this country relies on increased funding to our industry and its research institutions as well as maintaining regulations that are reasonable, efficient and predictable. These issues

will be a focus for the coming year and will be a topic for the Board of Directors at our April retreat.

I will also be carrying our message forward along with key industry leaders to the BIO Fly-in in Washington, DC in May. To learn more about our federal efforts please contact me.

Please get involved and support the bio-science industry.

Make sure to join us at the [Annual Meeting](#) April 7th 4-6pm to meet the Board and fellow members and to hear about key initiatives from the Governor's Office of Economic Development and International Trade.

Holli Baumunk

President and CEO
Colorado BioScience Association

Inside this issue:

- From the President 1
- Company News 2
- Annual Meeting 3
- Company Spotlight 4
- Sponsorship 5
- Upcoming Events 6

www.CoBioScience.com

Company News: CaridianBCT



Earlier this month the headline “CaridianBCT to be sold for \$2.6B” ran throughout industry publications.

As a stronghold in the local bioscience community we wanted to know what that means for the Colorado company. Recently, Tarra Ryerson, Global Corporate Communication Manager for CaridianBCT was able to answer a few questions and share some of the details about the acquisition.

CBSA: What does the acquisition mean for CaridianBCT?

CaridianBCT: The compelling strategic fit of CaridianBCT and Terumo will advance our position as a global leader and provide future growth opportunities for both organizations in the blood bank, hospital and biotech customer segments. We also believe this combination is ideal for our company, our employees, our customers and the patients we ultimately serve.

What operations will be affected?

Once the transaction closes, the CaridianBCT business and Terumo’s Transfusion business will combine and operate as a separate division within the Terumo organization.

Will the Colorado location become the transfusion business headquarters?

The global headquarters of the division will be located here, in Colorado with David Perez, CaridianBCT’s current President and CEO, becoming President and CEO of the combined division.

How will it affect Colorado?

Based on early knowledge of Terumo’s Transfusion business organization, we do not anticipate significant restructuring or job redundancies as a result of combining the businesses. We will capture the natural synergies that exist as we integrate the businesses. We do not anticipate we will understand the full impact for some time as further study will be required.

Do you see adding or losing jobs?

We do know that our day-to-day operations will not change in the near term. Any integration or combination of functions, products or regions will need to be evaluated more fully following the closing of the transaction. At this time, we are continuing with “business as usual” and remain steadfast to our vision, mission and values as well as to our strategic plan and our commitment to delivering on our 2011 plan.



“We are very excited about the prospect of being a part of this great company and believe the two organizations will be a powerful combination. “

David Perez
President and CEO
CaridianBCT



March 7, 2011 Notice Regarding the Acquisition of CaridianBCT

Terumo Corporation (Head Office: Shibuya-ku, Tokyo; President: Yutaro Shintaku - hereinafter “Terumo”) today announced that it has entered into a Stock Purchase Agreement to acquire all outstanding shares (the “Acquisition”) of CaridianBCT Holding Corp. (Head Office: Colorado, the United States— hereinafter “CaridianBCT”), a leading global provider in the blood transfusion industry as follows...

Full release

<http://www.caridianbct.com/layouts/uploads/CaridianBCT/Terumo-Corporation-Press-Release.pdf>

CBSA Annual Meeting



Thank you

On behalf of the members, board and staff of CBSA we sincerely thank Rick Jory for his service as Chair of the Board of Directors.

Rick's leadership, dedication and time has improved CBSA and the and the bioscience community of Colorado.

Please join us in thanking Rick at the all member meeting.

Rick Jory

President and CEO, Sandhill Scientific, Inc

Chair of Board of Directors

2009-2011

Moving CBSA Forward

As a member of CBSA participating in the annual meeting offers an opportunity to engage with the Board of Directors and leadership.

All Member Meeting

4:00 – 6:00 pm

April 7, 2011

Colorado National Golf Club

2700 Vista Parkway, Erie, Colorado 80516

Meeting Agenda

1. Welcome – Rick Jory, Board Chair – 4:00pm
2. Recognition of outgoing Board Members — Rick Jory - 4:05pm
3. Action Items – Rick Jory - 4:15pm
 - Minutes of the 2010 Meeting
 - Appointments to Board of Directors
4. Financial Accountability Report from the Board Treasurer, Norwood Robb - 4:25pm
5. 2010 Accomplishments Report from Board Chair, Rick Jory - 4:30pm
6. CBSA 2011 Activities Update from President & CEO, Holli Baumunk - 4:40pm
7. Presentation from Alice Kotrlík, Deputy Director and Sandi Moilanen, Interim Division Director- Colorado Office of Economic Development & International Trade - 4:45pm
8. Reception - 5:00pm

Company Spotlight: Baxa Corporation



www.baxa.com

At its inception in 1975, Baxa Corporation set a course towards patient safety. Throughout its more than thirty-five years of industry leadership, Baxa has been a leading provider of medical devices and systems that automate pharmacy operations. The company continues to launch innovative technological advances that drive patient safety practices.

In 2010, Baxa doubled its production cleanroom space and added assembly and warehouse space, expanding capacity to meet customer demand and ensure on-time product shipments to customers around the world. To make room for this expanded production, Baxa also opened a new corporate

headquarters, located at 9540 S Maroon Circle, Englewood, Colorado, encompassing 64,000 square feet of office and laboratory space. These new facilities – and the expansion of our R&D program space – underscore the company's commitment to delivering products that reduce pharmacy costs, improve IV room efficiency and enhance patient safety.

Currently, more than 3,000 hospitals worldwide use Baxa products every day to produce more than 450,000 safe medication doses. Over the past 35 years, the company has worked to set the standard for safety, speed and certainty in pharmacy dose preparation.



ExactaMix 2400 Compounder (EM2400) in use.

The ExactaMix 2400 Compounder (EM2400) is a 24-port automated compounding device for multi-source fluid mixing of both macro and micro ingredients down to 0.2 mL. Its ability to accommodate a large number of source ingredients reduces or eliminates the need for manual additions, making this the safest way to compound total parenteral nutrition (TPN) for adult, pediatric and neonatal patients. The EM2400 includes an integrated touch screen display, load cell, vial rack, barcode scanner and operating software.



Baxa corporate headquarters, Englewood, Colorado

Sponsorship Opportunities



*The Global Event
for Biotechnology*

June 27-30, 2011

Walter E. Washington
Convention Center
Washington, DC
convention.bio.org

Join the Colorado Pavilion

- A fraction of the cost of having your own booth.
- Exhibitor Opportunities starting at \$3,000
- Sponsorship Opportunities starting at \$1,000

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry.

Last year over 14,000 people attended with over 15% at the C-level, 28% were executive management, 24% directors, and 33% at manager level. Over 1700 companies, organizations and institutions exhibited at BIO 2010.

Contact April Giles, agiles@cobioscience.com

Colorado

Office of Economic
Development and
International
Trade



Sponsorship Opportunities Now Available

As a sponsor you help to make the conference happen and reach your target audience.

For information about becoming a sponsor, please contact April Giles, agiles@cobioscience.com.

- Presenting Partner - \$25,000
- Fourteeners Partners - \$15,000
- Flatirons Partner - \$10,000
- Lanyard Sponsor - \$7,500
- Peaks Partner - \$5,000
- Foothills Coffee Break Sponsors - \$2,500
- Half-Pipe Memory Stick - \$2,500

www.RockyMtnBioInvest.com



The Rocky Mountain Region's Unique Position

The Rocky Mountain region is the largest and most advanced area between both coasts, garnering more than \$11.5 billion dollars in financings and acquisitions since the end of 2007. In 2010, Colorado ranked in the top 10 states in the number of financing deals and dollars raised with our regional partners following close with Arizona in the top 15 and Utah in the top third of all states.

Upcoming Events

BioBoulder

March 29

5:30pm-7:00pm

Laudisio Italian Restaurant, 1710 29th Street, Boulder

Free for CBSA Members, \$50 Non-Members

All Member Meeting

April 7

4:00-6:00p.m.

Colorado National Golf Club, 2700 Vista Pkwy, Erie

Free for CBSA Members

Biobootcamp

April 14-15 9:00-5:00pm

Holland & Hart LLP

555 17th Street, Suite 3200, Denver

This program is open only to inventors, professionals, and entrepreneurs in the bioscience industry. This conference is provided at no cost to approved attendees.

Contact Susan Westberry at sdwestberry@hollandhart.com or 303-295-8273.

Applications must be received by March 25, 2011

Scientific Series: Personalized Medicine

April 28

7:30-10:30am

Scientific Education and Research Institute, 9005 Grant Street Suite 100, Thornton

Free to CBSA Members, Non-Members: \$50

Finance Seminar

Ernst & Young: A Life Science Accounting Update

New Date: May 4

4:00-6:00 p.m.

Republic Plaza Concourse Level, 370 17th Street, Denver

Free for CBSA Members, \$50 Non-Members

To register, please log into our database system at <https://netforum.avectra.com/eweb/StartPage.aspx?Site=CBSA>.

CBSA Staff

Holli Baumunk

President and CEO

hbaumunk@cobioscience.com

April Giles

Executive Vice President

agiles@cobioscience.com

Mae Desaire

Director of Marketing

mdesaire@cobioscience.com

Steve Ambriz

Operations Manager

sambriz@cobioscience.com

Find us on Facebook 

www.facebook.com/ColoradoBioScienceAssociation

Follow us on Twitter 

www.twitter.com/cobioscience

Join our group on  **LinkedIn**

<http://tinyurl.com/CBSALinkedInGroup>



<http://coloradobio.blogspot.com/>



www.youtube.com/cobioscience